4.1 Polypharmacy Identification & Medication Review

Why Pharmacotherapy Assessment Matters

Medication-related harm is one of the most modifiable risks in older adult care. For GERO-BC, pharmacotherapy assessment (TCO I-A-3) means systematically identifying what the older adult is actually taking, whether each drug still has a clear indication, and how the regimen contributes to current findings—falls, confusion, anorexia, incontinence, or unexplained decline. Assessment precedes Beers-based prescribing decisions (covered later); the nurse’s job here is to gather a complete, accurate picture and recognize red flags.

Defining Polypharmacy

Polypharmacy is most often operationalized as concurrent use of five or more medications. Numeric thresholds alone are incomplete: an older adult on four high-risk agents may be more endangered than someone on six well-indicated, carefully monitored drugs. Distinguish:

Prescribing cascades are high-yield for the exam: an adverse drug effect is misread as a new disease, and another medication is added. Classic patterns include calcium-channel-blocker edema treated with a diuretic, NSAID-related hypertension treated with another antihypertensive, and dopamine-agonist or antipsychotic effects treated with anticholinergics.

Sources of the Medication List

Older adults often have fragmented regimens across specialists, retail pharmacies, mail-order, hospital discharge lists, and family caregivers. A best-possible medication history includes:

1. Patient and caregiver interview — name, dose, frequency, route, and purpose in the person’s own words
2. Brown-bag review — bring all bottles, blister packs, samples, inhalers, eye drops, patches, and injectables
3. OTC and complementary products — analgesics, sleep aids, antacids, vitamins, herbals, CBD, topical agents
4. Pharmacy fill history / EHR reconciliation — compare prescribed vs. filled vs. taken
5. Shared or borrowed medications — common in households and assisted living social networks
6. Recently stopped drugs — residual effects and rebound (e.g., beta-blocker, benzodiazepine, SSRI)

Ask specifically about as-needed use frequency. A PRN opioid, benzodiazepine, or NSAID used daily is functionally a chronic medication and must be assessed for cumulative risk.

Structured Medication Review Steps

Use a consistent sequence so nothing is skipped:

1. Reconcile — build one active list from all sources; flag discrepancies
2. Match indication — for each drug, confirm the condition still exists and the drug addresses it
3. Check dose and duration — age-adjusted dosing, renal adjustment needs, time-limited drugs still running indefinitely
4. Assess adherence and administration — missed doses, crushing issues, inhaler technique, timing with meals
5. Screen adverse effects and geriatric syndromes — falls, delirium, constipation, dry mouth, orthostasis, bleeding, hypoglycemia
6. Identify high-risk combinations — see Section 4.2; note for collaborative deprescribing
7. Document and communicate — discrepancies, patient goals, and recommendations to the prescriber team

Adherence vs. Intentional Nonuse

Do not label every missed dose as “noncompliance.” Explore cost, complexity (pill burden, multiple daily dosing), cognitive impairment, dysphagia, fear of side effects, religious fasting, and conflicting advice from multiple clinicians. Cost-related nonadherence and regimen complexity are assessment findings that drive care planning—not moral failures.

High-Yield Assessment Findings Linked to Medications

When assessment reveals polypharmacy plus a geriatric syndrome, treat the medication list as a primary differential contributor—not an afterthought.

Deprescribing as an Assessment Outcome

Deprescribing is the supervised reduction or stop of medications when harms outweigh benefits or goals of care have changed. Assessment identifies candidates (e.g., long-term PPI without indication, duplicate anticholinergics, muscle relaxants for chronic nonspecific pain). Actual taper plans belong to collaborative practice; the GERO-BC nurse documents rationale, monitors withdrawal risk, and educates the patient and caregiver.

Special Populations and Settings

Medication review intensity should match setting and vulnerability:

• Hospital/SNF admission or transfer: Highest discrepancy risk—reconcile within institutional policy time frames and before the first dose whenever possible
• Home health and primary care: Reassess after any ED visit, specialist appointment, or new symptom cluster
• Cognitive impairment: Prefer caregiver/proxy + pharmacy fill data; observe pillbox organization and leftover counts
• End-of-life / changing goals: Preventive agents with long time-to-benefit (e.g., some primary-prevention therapies) become deprescribing candidates when comfort is the priority

Document who manages medications day to day, literacy/language needs, and whether blister packs or pharmacy synchronization are already in use. These details turn a static drug list into an actionable assessment.

Communication Pearls for the Exam

Frame findings as clinical safety issues: “Three anticholinergic agents plus new constipation and urinary retention” is more actionable than “patient is on too many meds.” Tie each concern to an observed syndrome, a missing indication, or a cascade hypothesis so the interprofessional team can act.

Exam tip: Polypharmacy identification is not a simple pill count. The tested skill is reconciling all sources, linking drugs to syndromes, spotting cascades, and framing deprescribing opportunities within person-centered goals.